The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Yet another experimental drug heavily touted by Pfizer Inc. has foundered in advanced testing, raising worries about productivity ...

Pfizer shares fell about 1.5% after sigvotatug vedotin failed to significantly improve survival in a late-stage lung cancer trial.

A pill to treat obesity caused liver injury in a clinical trial Pfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity drugs are in ...

Pfizer is drawing healthcare attention as its obesity, oncology, vaccine, and medicine programs shape a broader pipeline ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Pfizer said Friday it is halting the testing of a twice-daily obesity drug, citing side effects. The company said in a press release it will now focus its future efforts for the drug, danuglipron, on ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person ...